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ABSTRACT 
Objective: The main objective of this work was to synthesize and evaluate the novel 2,3-dihydro-1,3,4-oxadiazole and 4,5-dihydro-1,2,4-triazole 
derivatives for cytotoxic activities. 
Methods: The 2,3-dihydro-1,3,4-oxadiazole derivatives 4a-h were synthesized by cyclization of N'-(substituted-benzylidene) isonicotinohydrazide 
3a-e in refluxing acetic anhydride. The 2,3-dihydro-1,3,4-oxadiazole derivatives 4a-h were converted into the corresponding 4,5-dihydro-1,2,4-
triazoles 5a-h using ammonia. All the synthesized compounds were identified, depending on the physical and spectral data. Title compounds were 
assessed for their cytotoxic activity against human cancer cell line (MCF-7) by using Sulforhodamine B (SRB) colorimetric assay. 
Results: All the synthesized compounds showed characteristic peaks in FTIR, 1HNMR and Mass spectral analysis. The results of the in vitro cytotoxic 
activity revealed that the compound 4c exhibited equipotent cytotoxic activity with an IC50 value of 8.04 µM when compared with that of standard 
drug doxorubicin (IC50= 8.02 µM). The reminder compounds have shown good to moderate cytotoxic activities when compared with that of a 
reference standard.  
Conclusion: We synthesized a series of title compounds in quantitative yields. Most derivatives showed moderate to good cytotoxic activity. 
Keywords: 2,3-Dihydro-1,3,4-oxadiazole, 4,5-Dihydro-1,2,4-triazole, MCF-7, Anticancer 
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INTRODUCTION 
There are numerous literature reports confirming the multidirectional 
effect of compounds containing the 1,3,4-oxadiazole ring in its 
structure. 1,3,4-Oxadiazole derivatives showed numerous biological 
activities [1-14]. In addition, the 1,3,4-oxadiazole derivatives showed 
anti-proliferative properties against MCF-7 breast cancer cell Line [15-
17], ovarian cancer cell lines (ovcar-3 and Hela) [18, 19], human lung 
cancer cell line (L2987) [20] and colorectal cancer [21]. These 
compounds have different mechanisms of action, which is very 
important in view of the observed resistance of tumors to standard 
drug treatment. Moreover, some of the 1,3,4-oxadiazole derivatives 
are inhibitors of growth factors, enzymes, kinases and receptors that 
are mediated in cancer treatment [22-27].  
On the other hand, compounds having triazole moieties, such as 
vorozole, letrozole and anastrozole, appeared to be very effective 
aromatase inhibitors, which in turn prevented cancer, especially 
breast cancer [28-32]. Furthermore, certain 1,2,4-triazole 
derivatives have been reported as antitumor agents [33-35]. 
Inspired by these finding and in order to develop new anticancer 
therapeutic agents, we were encouraged to synthesize series of 2,3-
dihydro-1,3,4-oxadiazoles and their bioisosters, 4,5-dihydro-1,2,4-
triazoles, with incorporation of pyridine moiety, halogens, methoxy 
and methyl groups which are expected to allows simultaneous 
modulation of electronic, lipophilic, and steric parameters. These 
parameters can critically influence both the pharmacodynamic and 
pharmacokinetic properties of the synthesized compounds and 
expected to enhance their anticancer activities.  
MATERIALS AND METHODS  
Melting points are uncorrected and were determined on a Stuart 
melting point apparatus (Stuart Scientific, Redhill, UK). The FT-IR 
spectra (KBr) were recorded on Shimadzu FT-IR 110 
spectrophotometer (Shimadzu, Koyoto, Japan) by using 1% potassium 
bromide discs. 1H-NMR spectra were recorded on a Bruker proton 300 
MHz (Bruker, Munuch, Germany) spectrometer using DMSO-d6 as a 
solvent and tetramethylsilane (TMS) as an internal standard. Chemical 
shift values are listed in δ scale. Mass spectra were determined using a 
GC/MS Mat 112 S at the 70ev spectrometer. Elemental analysis (C, H, N) 
were performed on a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, 
CT, USA) at the microanalytical laboratories of the Faculty of Science, 
Cairo University. Completion of the reaction was monitored by thin-layer 
chromatography (TLC) using precoated aluminum sheets silica gel (Merck, 
60 F254). Visualization was accomplished with an ultraviolet UV lamp 
(Merck, Darmstadt, Germany). Synthesized compounds were purified 
by the re-crystallization process. The purity of the compounds was 
checked by a single spot in TLC and the solvent system for TLC was 
determined on a trial and error basis. All the chemicals and solvents 
used were of commercial grade. 
Experimental procedures 
Synthesis of N'-(substituted benzylidene) isonicotinohydrazide 
(3a-h) 
Isonicotinohydrazide 1 (0.001 mol), appropriate aromatic aldehyde 
2 (0.001 mol), ethanol (30 ml) and a catalytic amount of acetic acid 
were added to the round-bottomed flask (RBF) and the reaction 
mixture was refluxed for 3 h. The completion of the reaction was 
monitored by TLC. The reaction mixture was poured into crushed ice 
to obtain a solid product. The obtained precipitate was filtered 
under suction, washed thoroughly with water, dried and 
recrystallized from methanol.  
Synthesis of 1-(2-substituted phenyl-5-(pyridin-4-yl)-1,3,4-
oxadiazol-3(2H)-yl)ethanone (4 a-h) 
To arylidenearylhydrazides 3a-e (0.01 mol), acetic anhydride (40 
ml) was added and the reaction mixture was refluxed for 2 h. The 
crushed ice was added to the reaction mixture to obtain precipitate, 
which was filtered off and, washed with 10% aqueous solution of 
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NaHCO3 to remove the acetic acid. The obtained solid was 
recrystalized from ethanol. 
Synthesis of 1-(5-(4-substituted phenyl)-3-(pyridin-4-yl)-4,5-
dihydro-1,2,4-triazol-1-yl)ethanones (5a-h) 
Compounds 4a-h (0.01 mol) was added during 10 min to stirred and 
cooled solution of ammonia solution (10 ml) and water (10 ml). The 
temperature during the addition was kept below 20 °C. Then the 
reaction mixture was stirred for 2 h at room temperature. The 
reaction mixture was poured into crushed ice and acidify with 
hydrochloric acid to obtain precipitate, which was filtered off and, 
washed with water. The obtained solid was recrystallized from 
ethanol. IUPAC names and the molecular structures of the 
synthesized compounds 3a-h, 4a-h and 5a-h are shown in table 1. 
 
Table 1: List of the IUPAC name and the molecular structure of the synthesized compounds (3a-e, 4a-e and 5a-e) 
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Anticancer activities  
The Cytotoxic activity of the synthesized compounds was 
measured against human mammary carcinoma cell line (MCF7) 
in the National Cancer Institute, Cairo University. The screening 
involves a calculation of the percentage growth or the surviving 
fraction of the drug-treated cell lines compared with untreated 
control using Sulforhodamine B (SRB) colorimetric assay [36]. 
Cells were plated in 96-multiwell plate (104 cells/well) for 24 h 
before treatment with the compounds to allow attachment of 
cells to the wall of the plate. Different concentrations of the 
compound under test (0.0, 1.0, 2.5, 5.0 and 10.0 μg/ml) were 
added to the cell monolayer. Triplicate wells were prepared for 
each individual dose. Monolayer cells were incubated with the 
compounds for 48 h at 37 °C and in an atmosphere of 5% CO2. 
After 48 h, cells were fixed and stained for 30 min with 0.4% 
(wt/vol) SRB dissolved in 1% acetic acid. Excess unbound dye 
was removed by four washes with 1% acetic acid and the 
attached stain was recovered with Tris–EDTA buffer. Color 
intensity was measured in an ELISA reader. The relation 
between surviving fraction and drug concentration is plotted to 
get the survival curve of the tumor cell line after the specified 
compound. The results were described in the table 2. 
RESULTS AND DISCUSSION 
Chemistry 
In this study, N'-(substituted benzylidene) isonicotinohydrazides 3a-
h, 2,3-dihydro-1,3,4-oxadiazoles 4a-h and 4,5-dihydro-1,2,4-triazole 
derivatives 5a-h (table 1) were synthesized, of which compounds 3a-
d and 4a-d have been reported before [37]. 
The synthesis of 1-(2-substituted phenyl-5-(pyridin-4-yl)-1,3,4-
oxadiazol-3(2H)-yl)ethanones was performed in two steps: the synthesis 
of N'-(substituted benzylidene) isonicotinohydrazides 3a-h from the 
substituted aromatic aldehyde 2a-h and synthesis of 1-(2-substituted 
phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl) ethanones 4a-h from 
the Schiff’s bases 3a-h using acetic anhydride (fig. 1). On the other 
hand, the 2,3-dihydro-1,3,4-oxadiazole rings of compounds 4a-e 
were transformed into the corresponding 4,5-dihydro-1,2,4-triazole 
derivatives 5a-e via ring opening of the oxadiazole. 
The synthesis of N'-(substitutedbenzylidene) isonicotinohydrazides 3a-h 
shown to be simple and practical, achieving a good yield, as described in 
previous studies [37-39]. On the other hand, for the series of 1-(2-
substituted phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl) ethanones 
4a-h were synthesized according to the previously described procedures 
[36-39]. Substitutions at the phenyl moiety, reaction time and 
temperature of the reaction are the main parameters that identify the 
yield of the products [38, 40]. In this study, the reaction time and 
temperature of the reaction were adjusted to 3 h and 120 °C respectively 
to achieve yield in the range from 70% to 82%. Finally, the 1-(2-
substituted phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl) ethanones 
4a-h were reacted with ammonia to give 1-(5-(4-substituted phenyl)-3-
(pyridin-4-yl)-4,5-dihydro-1,2,4-triazol-1-yl)ethanones 5a-h in good 
yield via ring-opening rearrangement of the oxadiazole. 
During the synthesis procedure, thin layer chromatography (TLC) 
analysis was carried out to verify the formation of the synthesized 
compounds. The structural elucidation of these compounds was 
confirmed through 1H NMR, IR and mas spectral data. The IR spectrum 
for intermediate compounds 3a-h showed characteristic peaks of N-H 
around (3420 cm-1) and of C-O-NH of amide in range of 1632-1635 cm-1. 
The IR spectra for compounds 4a-h showed characteristic peaks of 
carbonyl of CH3C-O in the range of 1690-1695 cm-1. The IR spectra for 
final compounds 5a-h showed characteristic peaks of NH in the range of 
3205-3212 cm-1. The 1H NMR spectrum of the compounds 3a-h contains 
a multiplet in the range of 7.10-7.95 ppm for aromatic protons, a proton 
of NH appeared as singlet in the around 8.01 ppm which exchanged with 
D2O while a proton of CH=N appeared as singlet in the range of 8.18-
8.21 ppm. The 1H NMR spectra of the compounds 4a-h contains singlet 
around 2.26 ppm for CH3 protons, protons of CH of oxadiazole ring 
appeared as a singlet in the range of 5.53-5.67 ppm and aromatic 
protons appeared in the range of 7.20-8.21 ppm. The 1H NMR spectra of 
the final compounds 5a-h contains singlet around 6.15 and 2.40 ppm 
attributed for CH and NH protons of triazole ring, respectively. Mass 
spectra proved parent peaks of the synthesized compounds confirming 
the molecular weight. 
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Fig. 1: Synthesis of compounds 3a-e, 4a-e and 5a-e investigated in this work 
 
Spectral characterization of synthesized compounds 
N'-benzylideneisonicotinohydrazide (3a): Yield 73%, mp 86-88 ° 
C. IR spectrum, ν, cm-1: 1633, 1650, 3052, 3420. 1H NMR (300 MHz, 
DMSO-d6): 7.20-7.93 (m, 9H, ArH), 8.01 (s, 1H, NH, exch. With D2O), 
8.20 (s, 1H, CH=N). MS: (m/z) 225 (M+) observed for C13H13N3O, Anal 
calcd: C, 69.32; H, 4.92; N, 18.66; found: C, 69.59; H, 5.15; N, 18.92;  
N'-(4-methoxybenzylidene)isonicotinohydrazide (3b): Yield 
80%, mp 102-104 °C. IR spectrum, ν, cm-1: 1632, 1650, 3061, 3424. 
1H NMR (300 MHz, DMSO-d6): 3.85 (s, 3H, OCH3), 7.21-7.89 (m, 8H, 
ArH), 8.08 (s, 1H, NH, exch. With D2O), 8.21 (s, 1H,-CH=N). MS: (m/z) 
255 (M+) observed for C14H13N3O2, Anal calcd: C, 65.87; H, 5.13; N, 
16.46; found: C, 65.39; H, 5.19; N, 16.58; 
N'-(4-methylbenzylidene)isonicotinohydrazide (3c): Yield 77%, 
mp 113-115 °C. IR spectrum, ν, cm-1: 1635, 1652, 3063, 3424. 1H 
NMR (300 MHz, DMSO-d6): 2.51 (s, 3H, CH3), 7.31-7.95 (m, 8H, ArH), 
8.10 (s, 1H, NH, exch. With D2O), 8.18 (s, 1H,-CH=N). MS: (m/z) 239 
(M+) observed for C14H13N3O, Anal calcd: C, 70.28; H, 5.48; N, 17.56; 
found: C, 70.49; H, 5.29; N, 17.88; 
(N'-(4-chlorobenzylidene)isonicotinohydrazide (3d): Yield 72%, 
mp 105-107 °C. IR spectrum, ν, cm-1: 1634, 1651, 3059, 3422. 1H 
NMR (300 MHz, DMSO-d6): 7.30-7.96 (m, 8H, ArH), 8.00 (s, 1H, NH, 
exch. With D2O), 8.18 (s, 1H,-CH=N). MS: (m/z) 259 (M+) observed 
for C13H10ClN3O, Anal calcd: C, 60.12; H, 3.88; N, 16.18; found: C, 
60.41; H, 4.11; N, 16.52;  
N'-(4-bromobenzylidene)isonicotinohydrazide (3e): Yield 74%, 
mp 101-103 °C. IR spectrum, ν, cm-1: 1635, 1650, 3060, 3420. 1H 
NMR (300 MHz, DMSO-d6): 7.10-7.95 (m, 8H, ArH), 8.02 (s, 1H, NH, 
exch. With D2O), 8.19 (s, 1H,-CH=N). MS: (m/z) 305 (M++2), 303 (M+) 
observed for C13H10BrN3O, Anal calcd: C, 51.34; H, 3.31; N, 13.82; 
found: C, 51.49; H, 3.18; N, 13.56; 
N'-(4-fluorobenzylidene)isonicotinohydrazide (3f): Yield 70%, 
mp 109-111 °C. IR spectrum, ν, cm-1: 1633, 1653, 3064, 3421. 1H 
NMR (300 MHz, DMSO-d6): 7.23-8.12 (m, 8H, ArH), 8.02 (s, 1H, NH, 
exch. With D2O), 8.21 (s, 1H,-CH=N). MS: (m/z) 243 (M+) observed 
for C13H10FN3O, Anal calcd: C, 64.19; H, 4.14; N, 17.28; found: C, 
64.54; H, 3.96; N, 17.55; 
(N'-(3-chlorobenzylidene)isonicotinohydrazide (3g): Yield 72%, 
mp 99-101 °C. IR spectrum, ν, cm-1: 1632, 1650, 3059, 3420. 1H NMR 
(300 MHz, DMSO-d6): 7.28-7.92 (m, 8H, ArH), 8.01 (s, 1H, NH, exch. 
With D2O), 8.19 (s, 1H,-CH=N). MS: (m/z) 259 (M+) observed for 
C13H10ClN3O, Anal calcd: C, 60.12; H, 3.88; N, 16.18; found: C, 59.90; 
H, 3.94; N, 16.23; 
N'-(2-bromobenzylidene)isonicotinohydrazide (3h): Yield 69%, 
mp 97-99 °C. IR spectrum, ν, cm-1: 1633, 1652, 3065, 3424. 1H NMR 
(300 MHz, DMSO-d6): 7.19-7.98 (m, 8H, ArH), 8.00 (s, 1H, NH, exch. 
With D2O), 8.18 (s, 1H,-CH=N). MS: (m/z) 305 (M++2), 303 (M+) 
observed for C13H10BrN3O, Anal calcd: C, 51.34; H, 3.31; N, 13.82; 
found: C, 51.21; H, 3.62; N, 13.93; 
1-(2-Phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4a): Yield 70%, mp 112-114 °C. IR spectrum, ν, cm-1: 
1690, 1625, 2950. 1H NMR (300 MHz, DMSO-d6): 2.27 (s, 3H, CH3), 
5.51 (s, 1H, CH, oxadiazole), 7.10-7.85 (m, 9H, ArH). MS: (m/z) 267 
(M+) observed for C15H13N3O2, Anal calcd: C, 67.40; H, 4.90; N, 15.72; 
found: C, 67.80; H, 4.79; N, 15.58;  
1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-
3(2H)-yl)ethanone (4b): Yield 77 %, mp 127-129 °C. IR spectrum, 
ν, cm-1: 1691, 1620, 2980. 1H NMR (300 MHz, DMSO-d6): 2.27 (s, 3H, 
CH3), 3.88 (s, 3H, OCH3), 5.53 (s, 1H, CH, oxadiazole), 7.20-7.91 (m, 
8H, ArH). MS: (m/z) 297 (M+) observed for C16H15N3O3, Anal calcd: C, 
64.64; H, 5.09; N, 14.13; found: C, 64.35; H, 5.27; N, 13.89; 
1-(5-(Pyridin-4-yl)-2-p-tolyl-1,3,4-oxadiazol-3(2H)-yl)ethanone 
(4c): Yield 73%, mp 90-92 °C. IR spectrum, ν, cm-1: 1690, 1625, 
2982. 1H NMR (300 MHz, DMSO-d6): 2.25 (s, 3H, CH3), 2.51(s, 3H, 
CH3), 5.52 (s, 1H, CH, oxadiazole), 7.10-7.91 (m, 8H, ArH). MS: (m/z) 
281 (M+) observed for C16H15N3O2, Anal calcd: C, 68.31; H, 5.37; N, 
14.94; found: C, 68.61; H, 5.78; N, 14.79; 
1-(2-(4-Chlorophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4d): Yield 78%, mp 121-123 °C. IR spectrum, ν, cm-1: 
1695, 1620, 2985. 1H NMR (300 MHz, DMSO-d6): 2.26 (s, 3H, CH3), 
5.52 (s, 1H, CH, oxadiazole), 7.30-7.96 (m, 8H, ArH). MS: (m/z) 301 
(M+) observed for C15H12ClN3O2, Anal calcd: C, 59.71; H, 4.01; N, 
13.93; found: C, 59.44; H, 4.38; N, 13.65; 
1-(2-(4-Bromophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4e): Yield 82%, mp 160-162 °C. IR spectrum, ν, cm-1: 
1690, 1621, 2982. 1H NMR (300 MHz, DMSO-d6): 2.26 (s, 3H, CH3), 
5.53 (s, 1H, CH, oxadiazole), 7.20-7.91 (m, 8H, ArH). MS: (m/z) 349 
(M++2), 347 (M+) observed for C15H12BrN3O2, Anal calcd: C, 52.04; H, 
3.49; N, 12.14; found: C, 52.34; H, 3.58; N, 12.52; 
1-(2-(4-Fluorophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4f): Yield 77%, mp 125-127 °C. IR spectrum, ν, cm-1: 
1695, 1620, 2985. 1H NMR (300 MHz, DMSO-d6): 2.25 (s, 3H, CH3), 
5.67 (s, 1H, CH, oxadiazole), 7.45-8.21 (m, 8H, ArH). MS: (m/z) 285 
(M+) observed for C15H12FN3O2, Anal calcd: C, 63.15; H, 4.24; N, 
14.73; found: C, 62.91; H, 4.52; N, 14.88; 
1-(2-(3-Chlorophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4g): Yield 76%, mp 117-119 °C. IR spectrum, ν, cm-1: 
1696, 1624, 2988. 1H NMR (300 MHz, DMSO-d6): 2.26 (s, 3H, CH3), 
5.59 (s, 1H, CH, oxadiazole), 7.42-7.99 (m, 8H, ArH). MS: (m/z) 301 
(M+) observed for C15H12ClN3O2, Anal calcd: C, 59.71; H, 4.01; N, 
13.93; found: C, 59.84; H, 4.27; N, 14.16; 
1-(2-(3-Bromophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)ethanone (4h): Yield 75%, mp 140-142 °C. IR spectrum, ν, cm-1: 
1695, 1624, 2986. 1H NMR (300 MHz, DMSO-d6): 2.26 (s, 3H, CH3), 
5.62 (s, 1H, CH, oxadiazole), 7.40-8.08 (m, 8H, ArH). MS: (m/z) 349 
(M++2), 347 (M+) observed for C15H12BrN3O2, Anal calcd: C, 52.04; H, 
3.49; N, 12.14; found: C, 52.19; H, 3.82; N, 11.94; 
1-(5-Phenyl-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-triazol-1-
yl)ethanone (5a): Yield 62%, mp 110-112 °C. IR spectrum, ν, cm-1: 
1699, 1625, 3010, 3210. 1H NMR (300 MHz, DMSO-d6): 2.31(s, 3H, 
CH3), 2.41(s, 1H, NH, triazole), 6.20 (s, 1H, CH, triazole), 7.15-7.82 (m, 
9H, ArH). MS: (m/z) 266 (M+) observed for C15H14N4O, Anal calcd: C, 
67.65; H, 5.30; N, 21.04; found: C, 67.50; H, 5.54; N, 20.86;  
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triazol-1-yl)ethanone (5b): Yield 75%, mp 139-141 °C. IR 
spectrum, ν, cm-1: 1701, 1625, 2997, 3208. 1H NMR (300 MHz, 
DMSO-d6): 2.31(s, 3H, CH3), 2.39 (s, 1H, NH, triazole), 3.92 (s, 3H, 
OCH3), 6.21 (s, 1H, CH, triazole), 7.32-8.12 (m, 8H, ArH). MS: (m/z) 
296 (M+) observed for C16H16N4O2, Anal calcd: C, 64.85; H, 5.44; N, 
18.91; found: C, 64.66; H, 5.65; N, 19.09; 
1-(3-(Pyridin-4-yl)-5-p-tolyl-4,5-dihydro-1,2,4-triazol-1-
yl)ethanone (5c): Yield 67%, mp 100-102 °C. IR spectrum, ν, cm-1: 
1690, 1625, 2982, 3212. 1H NMR (300 MHz, DMSO-d6): 2.24 (s, 3H, 
CH3), 2.52 (s, 3H, CH3), 2.40 (s, 1H, NH, triazole), 6.12 (s, 1H, CH, 
triazole), 7.19-8.01 (m, 8H, ArH). MS: (m/z) 280 (M+) observed for 
C16H15N4O, Anal calcd: C, 68.55; H, 5.75; N, 19.99; found: C, 68.81; H, 
5.98; N, 19.81; 
1-(5-(4-Chlorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-
triazol-1-yl)ethanone (5d): Yield 77%, mp 132-134 °C. IR 
spectrum, ν, cm-1: 1695, 1620, 2985, 3205. 1H NMR (300 MHz, 
DMSO-d6): 2.28 (s, 3H, CH3), 2.38 (s, 1H, NH, triazole), 6.15 (s, 1H, CH, 
triazole), 7.38-8.13 (m, 8H, ArH). MS: (m/z) 300 (M+) observed for 
C15H13ClN4O, Anal calcd: C, 59.91; H, 4.36; N, 18.63; found: C, 59.76; 
H, 4.21; N, 18.40; 
1-(5-(4-Bromophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-
triazol-1-yl)ethanone (5e): Yield 79%, mp 136-138 °C. IR 
spectrum, ν, cm-1: 1700, 1621, 2996, 3210. 1H NMR (300 MHz, 
DMSO-d6): 2.29 (s, 3H, CH3), 2.40 (s, 1H, NH, triazole), 6.18 (s, 1H, CH, 
triazole), 7.27-7.98 (m, 8H, ArH). MS: (m/z) 346 (M++2), 344 (M+) 
observed for C15H13BrN4O, Anal calcd: C, 52.19; H, 3.80; N, 16.32; 
found: C, 51.98; H, 3.98; N, 16.49; 
1-(5-(4-Fluorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-
triazol-1-yl)ethanone (5f): Yield 77%, mp 141-143 °C. IR 
spectrum, ν, cm-1: 1705, 1625, 2997, 3214. 1H NMR (300 MHz, 
DMSO-d6): 2.32 (s, 3H, CH3), 2.41 (s, 1H, NH, triazole), 6.14 (s, 1H, CH, 
triazole), 7.56-8.42 (m, 8H, ArH). MS: (m/z) 284 (M+) observed for 
C15H13FN4O, Anal calcd: C, 63.37; H, 4.61; N, 19.71; found: C, 62.99; H, 
4.86; N, 19.49; 
1-(5-(3-Chlorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-
triazol-1-yl)ethanone (5g): Yield 74%, mp 135-137 °C. IR 
spectrum, ν, cm-1: 1692, 1622, 2989, 3208. 1H NMR (300 MHz, 
DMSO-d6): 2.27 (s, 3H, CH3), 2.39 (s, 1H, NH, triazole), 6.13 (s, 1H, CH, 
triazole), 7.34-8.12 (m, 8H, ArH). MS: (m/z) 300 (M+) observed for 
C15H13ClN4O, Anal calcd: C, 59.91; H, 4.36; N, 18.63; found: C, 59.64; 
H, 4.63; N, 18.83; 
1-(5-(3-Bromophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-
triazol-1-yl)ethanone (5h): Yield 79%, mp 139-141 °C. IR 
spectrum, ν, cm-1: 1704, 1624, 3005, 3218. 1H NMR (300 MHz, 
DMSO-d6): 2.28 (s, 3H, CH3), 2.42 (s, 1H, NH, triazole), 6.17 (s, 1H, CH, 
triazole), 7.33-8.16 (m, 8H, ArH). MS: (m/z) 346 (M++2), 344 (M+) 
observed for C15H13BrN4O, Anal calcd: C, 52.19; H, 3.80; N, 16.32; 
found: C, 52.43; H, 3.52; N, 16.14; 
Cytotoxic activity 
Cytotoxic activity results were summarized in table 2. All the 
synthesized were evaluated to their cytotoxic activity against breast 
cancer cell line MCF7. Most of the tested compounds exhibited 
moderate to good cytotoxic activity with percentage inhibition in cell 
proliferation at an IC50 value of 9.84 and 39.21 µM. 
With regard to the benzylidene isonicotinohydrazides 3a-h, the 
compounds 3a-h exhibited moderate to good cytotoxic activity with 
IC50 ranges IC50 17.26-38.01 µM when compared to the reference 
standard doxorubicin (IC50, 8.02 µM), while the compound 3d showed 
the best activity among this series with IC50 value of 16.28 µM. 
Cyclization of 3a-h into the corresponding 2,3-dihydro-1,3,4-
oxadiazoles 4a-h resulted in an increased in cytotoxic activity with 
IC50 ranges 8.04-27.08 µM. The compound 4d showed equipotent 
activity (IC50, 8.04 µM) to that of the reference standard, doxorubicin 
(IC50, 8.02 µM). Finally, the ring transformation of 2,3-dihydro-1,3,4-
oxadiazoles 4a-h into the corresponding 4,5-dihydro-1,2,4-triazoles 
5a-h resulted in slightly decrease in cytotoxic activity with IC50 
ranges 9.78-28.54 µM. The type and position of substituent on 
phenyl moiety greatly affect anticancer activities. 
  
Table 2: In vitro cytotoxic activity of the synthesized compounds against MCF-7 cell line 
Compound No Compound concentration (µM) IC50 (µM) 
5 µM 12.5 µM 25 µM 50 µM  
Surviving fraction (mean±SEM)a 
3a 0.983±0.057 0.695±0.041 0.364±0.041 0.376±0.043 19.52 
3b 0.721±0.031 0.465±0.041 0.381±0.029 0.181±0.031 18.22 
3c 0.765±0.051 0.569±0.028 0.445±0.027 0.385±0.021 16.28 
3d 0.397±0.031 0.281±0.026 0.229±0.015 0.295±0.004 17.26 
3e 0.333±0.051 0.312±0.023 0.121±0.035 0.110±0.001 17.43 
3f 0.745±0.182 0.478±0.087 0.393±0.065 0.192±0.068 18.65 
3g 0.866±0.060 0.651±0.025 0.582±0.030 0.397±0.008 36.45 
3h 0.882±0.038 0.655±0.017 0.568±0.011 0.422±0.076 38.01 
4a 0.373±0.033 0.281±0.021 0.152±0.032 0.141±0.013 15.21 
4b 0.352±0.012 0.226±0.015 0.291±0.045 0.425±0.043 11.20 
4c 0.299±0.110 0.281±0.170 0.279±0.024 0.289±0.042 8.04 
4d 0.682±0.017 0.495±0.023 0.096±0.034 0.099±0.021 12.01 
4e 0.452±0.018 0.262±0.022 0.365±0.021 0.280±0.015 10.22 
4f 0.681±0.182 0.485±0.087 0.321±0.065 0.121±0.068 14.73 
4g 0.853±0.013 0.517±0.052 0.379±0.043 0.345±0.091 25.62 
4h 0.841±0.022 0.678±0.018 0.454±0.027 0.235±0.015 27.08 
5a 0.378±0.070 0.287±0.017 0.158±0.050 0.145±0.021 16.23 
5b 0.713±0.038 0.482±0.076 0.352±0.008 0.117±0.003 12.54 
5c 0.589±0.16 0.487±0.069 0.254±0.081 0.146±0.065 9.78 
5d 0.563±0.032 0.312±0.017 0.212±0.011 0.289±0.021 13.09 
5e 0.663±0.012 0.412±0.015 0.312±0.045 0.189±0.043 11.59 
5f 0.698±0.090 0.435±0.026 0.391±0.072 0.102±0.034 15.25 
5g 0.832±0.061 0.644±0.015 0.329±0.071 0.342±0.015 26.62 
5h 0.853±0.043 0.617±0.061 0.389±0.070 0.325±0.093 28.54 
Doxorubicin 0.314±0.032 0.309±0.016 0.251±0.023 0.266±0.032 8.02 
aEach value is the mean of three values±standard error. 
 
CONCLUSION 
In this study, a series of benzylidene isonicotinohydrazide 
derivatives 3a-h, 1,3,4-oxadiazol-3(2H)-yl) ethanones 4a-h and 1-(5-
(4-substituted phenyl)-3-(pyridin-4-yl)-4,5-dihydro-1,2,4-triazol-1-
yl) ethanones 5a-h have been synthesized and evaluated for their 
antitumor activities. These compounds were characterized using 
standard spectroscopic and spectrometric techniques, confirming 
the integrity of these molecules. The biological activities of all of the 
synthesized compounds were examined against breast cancer MCF7 
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cell lines. The results of in vitro anticancer activity indicated that 
most of the tested compounds exhibited moderate to good activities. 
On the other hand, compound 4c exhibited nearly similar cytotoxic 
activity (IC50= 8.04 µM) to that of the standard drug doxorubicin 
(IC50= 8.02 µM).  
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